Patel, D.M., Foreman, P.M., Nabors, L.B., et al. (2016) Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Human Gene Therapy Clinical Development, 27, 69-78.
https://doi.org/10.1089/humc.2016.031

has been cited by the following article:

• TITLE: Oncolytic Engineering of ICP34.5 and LAT of Herpes Simplex Virus Type 1

  AUTHORS: Wenqi Cai, Ying Zhang, Qi Huang, Ying Xiang, Hongwu Xin

  KEYWORDS: Herpes Simplex Virus, Oncolytic Herpes Simplex Virus, Latency-Associated Transcript, ICP34.5

  JOURNAL NAME: Yangtze Medicine, Vol.5 No.2, April 15, 2021

  ABSTRACT: Oncolytic virus (OV) is a kind of virus that can preferentially infect and kill tumor cells. The second oncolytic virus drug was oncolytic herpes simplex virus (oHSV) Talimogene Laherparepvec (T-VEC). HSV-1 infectious cell culture protein 34.5 (ICP34.5) and latency-associated transcript (LAT) genes are closely related to virus selective infection and latent infection. Their engineering is essential for constructing efficient and safe oHSV. We summarized the mechanisms of ICP34.5 and LAT in the course of HSV-1 infection and reviewed the engineered oHSVs. We are aimed to provide an insight in developing oHSV in the future.